|
|
Volumn 47, Issue 10, 2008, Pages 1303-1310
|
|
Value of targeted therapies for renal cell cancer;Der stellenwert der targeted-therapie beim nierenzellkarzinom
a
a
|
|
Author keywords
Cytokines; Metastasis; Multikinase inhibitors; Renal cell cancer; Tyrosine kinase inhibitor
|
|
Indexed keywords
ALPHA INTERFERON;
BEVACIZUMAB;
CYTOKINE;
ERLOTINIB;
EVEROLIMUS;
FLT3 LIGAND;
GLYCOPROTEIN P;
LAPATINIB;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
PLACEBO;
RAF PROTEIN;
RAPAMYCIN;
SORAFENIB;
STEM CELL FACTOR;
SUNITINIB;
TEMSIROLIMUS;
THALIDOMIDE;
VASCULOTROPIN;
ADJUVANT CHEMOTHERAPY;
ANTIANGIOGENIC ACTIVITY;
CANCER ADJUVANT THERAPY;
CANCER THERAPY;
CLINICAL STUDY;
DISEASE FREE SURVIVAL;
DRUG APPROVAL;
DRUG DOSE ESCALATION;
GASTROINTESTINAL SYMPTOM;
GERMANY;
HUMAN;
HYPERGLYCEMIA;
HYPERLIPIDEMIA;
KIDNEY CANCER;
LIVER DISEASE;
METASTASIS;
MOLECULAR THERAPY;
MULTIDRUG RESISTANCE;
PAIN;
PERIPHERAL EDEMA;
RASH;
REVIEW;
RISK FACTOR;
TREATMENT RESPONSE;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BENZENESULFONATES;
CARCINOMA, RENAL CELL;
DISEASE PROGRESSION;
DRUG DELIVERY SYSTEMS;
DRUG RESISTANCE, MULTIPLE;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
INDOLES;
KIDNEY NEOPLASMS;
NEOPLASM STAGING;
PYRIDINES;
PYRROLES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SIROLIMUS;
SURVIVAL RATE;
|
|
EID: 53249117351
PISSN: 03402592
EISSN: None
Source Type: Journal
DOI: 10.1007/s00120-008-1746-x Document Type: Review |
|
Times cited : (9)
|
|
References (35)
|
